3371 Stock Overview
A biopharmaceutical company, develops products to defeat serious illness.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Corbus Pharmaceuticals Holdings, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$44.20 |
52 Week High | US$49.40 |
52 Week Low | US$16.90 |
Beta | 2.52 |
11 Month Change | 13.33% |
3 Month Change | 19.46% |
1 Year Change | n/a |
33 Year Change | 5.13% |
5 Year Change | -75.44% |
Change since IPO | -44.40% |
Recent News & Updates
Recent updates
Shareholder Returns
3371 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 7.8% | -2.1% | -0.5% |
1Y | n/a | -19.2% | 1.6% |
Return vs Industry: Insufficient data to determine how 3371 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 3371 performed against the German Market.
Price Volatility
3371 volatility | |
---|---|
3371 Average Weekly Movement | 12.1% |
Biotechs Industry Average Movement | 6.5% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.5% |
10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 3371's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 3371's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 19 | Yuval Cohen | www.corbuspharma.com |
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings.
Corbus Pharmaceuticals Holdings, Inc. Fundamentals Summary
3371 fundamental statistics | |
---|---|
Market cap | €491.48m |
Earnings (TTM) | -€31.26m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-15.7x
P/E RatioIs 3371 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
3371 income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$23.54m |
Gross Profit | -US$23.54m |
Other Expenses | US$10.22m |
Earnings | -US$33.76m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -3.16 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 13.4% |
How did 3371 perform over the long term?
See historical performance and comparison